Abstract: A hot-melt adhesive composition comprises a blend of at least one acidic polymer and at least one basic polymer. At least one of the polymers is a hot-melt adhesive. Thermally reversible crosslinks are formed between each of the two polymers. These crosslinks impart cohesive strength to the applied adhesive, without sacrificing ease of processing.
Type:
Grant
Filed:
March 15, 2001
Date of Patent:
October 5, 2004
Assignee:
3M Innovative Properties Company
Inventors:
Peter A. Stark, Audrey A. Sherman, Albert I. Everaerts
Abstract: The present invention generally provides a method of measuring the biological activity of Coagulation Factor VIIa (Factor VIIa). Specifically, the present invention provides a method for directly measuring the activity of Factor VIIa in a plasma sample. More specifically, the present invention provides a method for utilizing Factor VIIa activity as a bio-marker to monitor Factor VIIa inhibition to screen compounds which are able to inhibit the biological activity of Factor VIIa.
Type:
Grant
Filed:
May 8, 2002
Date of Patent:
August 10, 2004
Assignee:
Warner-Lambert Company
Inventors:
Liguo Chi, Robert Joseph Leadley, Jr., Yun-Wen Peng
Abstract: The present invention relates to a method of inhibiting matrix metalloproteinases using compounds that are dibenzofuran sulfonamide derivatives having the Formula I
More particularly, the present invention relates to a method of treating diseases in which matrix melatoproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, arthritis, or other autoimmune or inflammatory diseases dependent upon tissue invasion by leukocytes.
Type:
Grant
Filed:
March 2, 1999
Date of Patent:
September 23, 2003
Assignee:
Warner-Lambert Company
Inventors:
Patrick Michael O'Brien, Joseph Armand Picard, Drago Robert Sliskovic, Andrew David White
Abstract: The present invention relates to a method of inhibiting matrix metalloproteinases using compounds that are dibenzofuran sulfonamide derivatives having the Formula I
More particularly, the present invention relates to a method of treating diseases in which matrix metalloproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, arthritis, or other autoimmune or inflammatory diseases dependent upon tissue invasion by leukocytes.
Type:
Grant
Filed:
June 4, 2002
Date of Patent:
September 16, 2003
Assignee:
Warner-Lambert Company
Inventors:
Patrick Michael O'Brien, Joseph Armand Picard, Drago Robert Sliskovic, Andrew David White
Abstract: The instant invention is a series of benzothiazine dioxides, or a pharmaceutically acceptable salt thereof, which are potent endothelin A antagonists with profound in vitro activity, and improved syntheses for the Formula 1
The compounds are useful in treating elevated levels of endothelin, essential renovascular malignant and pulmonary hypertension, cerebral infarction, cerebral ischemia, congestive heart failure, and subarachnoid hemorrhage.
Type:
Grant
Filed:
December 5, 2001
Date of Patent:
April 8, 2003
Assignee:
Warner-Lambert Company
Inventors:
Amy Mae Bunker, Xue-Min Cheng, Annette Marian Doherty, Jeremy John Edmunds, Gerald David Kanter, Chitase Lee, Joseph Thomas Repine, Richard William Skeean
Abstract: The present invention provides compounds of Formula I shown below.
The present invention also provides methods of treating or preventing 3 inflammation or atherosclerosis, and a pharmaceutical composition that contains a compound of Formula I.
Type:
Grant
Filed:
May 15, 2001
Date of Patent:
March 4, 2003
Assignee:
Warner-Lambert Company
Inventors:
David Thomas Connor, William Howard Roark, Karen Elaine Sexton, Roderick Joseph Sorenson
Abstract: The instant invention is a series of benzothiazine dioxides, or a pharmaceutically acceptable salt thereof, which are potent endothelin A antagonists with profound in vitro activity, and improved syntheses for the Formula I
The compounds are useful in treating elevated levels of endothelin, essential renovascular malignant and pulmonary hypertension, cerebral infarction, cerebral ischemia, congestive heart failure, and subarachnoid hemorrhage.
Type:
Grant
Filed:
March 27, 2001
Date of Patent:
August 27, 2002
Assignee:
Warner-Lambert Company
Inventors:
Amy Mae Bunker, Xue-Min Cheng, Annette Marian Doherty, Jeremy John Edmunds, Gerald David Kanter, Chitase Lee, Joseph Thomas Repine, Richard William Skeean